MMDesign
PulseAugur coverage of MMDesign — every cluster mentioning MMDesign across labs, papers, and developer communities, ranked by signal.
- 2026-10-29 research_milestone MoleculeMind's MMDesign platform achieved a 95% success rate in de novo drug design projects, with 18 out of 19 yielding lab-confirmed binders. source
- 2026-06-06 product_launch MoleculeMind announced a breakthrough with its MMDesign platform for AI-powered de novo biologics design. source
1 day(s) with sentiment data
-
MoleculeMind's MMDesign achieves 95% success rate in de novo drug design
MoleculeMind's MMDesign platform has demonstrated significant success in de novo drug design, according to a recent technical report. The platform achieved a high success rate, with 18 out of 19 projects yielding lab-co…
-
AI platform QuantaMind simulates molecular dynamics with near-DFT accuracy
QuantaMind, an AI platform developed by Molecular Mind, has achieved a significant breakthrough in molecular dynamics simulation, as reported in Science Advances. This platform can now simulate reactive molecular dynami…
-
MoleculdOS AI platform designs novel cyclic peptides and nanobodies
MoleculdOS, an AI-driven drug design platform from Chinese biotech firm MoleculdOS, has demonstrated its capabilities in designing novel cyclic peptides for protein-protein interaction targets like p53-MDM2 and PD-L1. T…
-
Molecule Mind launches AI operating system for biological R&D
Professor Xu Jinbo's team at Molecule Mind has officially launched MoleculeOS, an AI-native operating system designed for biological research and development. This system aims to transition AI from a single-point tool t…
-
AI Protein Design Firm MoleculeMind Secures Over $100M in Series A Funding
MoleculeMind, an AI protein design platform, has secured over $100 million in Series A funding. The investment, led by Blue Horizon Capital and Pudong Venture Capital, signals a shift in the AI for Science sector toward…
-
MoleculeMind's MMDesign platform achieves 90% success in AI nanobody design
MoleculeMind has announced a significant advancement in AI-driven biologics design using its MMDesign platform. The platform has demonstrated a success rate exceeding 90% in de novo nanobody design. This breakthrough wa…